兼任：

国家重点研发计划项目首席科学家

中华医学会内科学分会副主任委员

中国医师协会心血管内科医师分会副会长

中国医院协会心脏康复管理委员会常务副会长兼秘书长

上海市医师协会心血管内科医师分会会长

中国房颤中心联盟左心耳封堵工作委员会主任委员

世界华人心血管医师协会常务副会长兼秘书长（WACC）

中国胸痛中心联盟副主席

中国房颤中心联盟副主席

中国房颤中心房颤顺盈副院长

中国心脏康复联盟执行主席

上海市胸痛中心联盟执行主席

……

Dr. Xu is one of nationally famous cardiologists with good reputation. He is also the chief physician, director of the Heart Center of Shanghai Tenth People's Hospital, director of the Institute of Pan Vascular Diseases, Tongji University School of Medicine, and tenured professor of Tongji University. He was awarded The State Council Special Allowance by National government, also honored the model worker by Shanghai government.

Concurrent academic title:

Chief Scientist of National Key R&D Program

Vice Chairman of Internal Medicine Branch of Chinese Medical Association

Vice President of Cardiovascular Medicine Branch of Chinese Medical Doctor Association

Executive Vice President and Secretary General of Cardiac Rehabilitation Management Committee of Chinese Hospital Association

Chairman of Cardiovascular Medicine Branch of Shanghai Medical Association

Chairman of the Left Atrial Appendage Occlusion Working Committee of the China Atrial Fibrillation Center Alliance

Executive Vice President and Secretary General of the World Association of Chinese Cardiovascular Physicians (WACC)

Vice Chairman of China Chest Pain Center Alliance

Vice Chairman of China Atrial Fibrillation Center Alliance

Vice President of Atrial Fibrillation College of China Atrial Fibrillation Center

Executive Chairman of China Cardiac Rehabilitation Alliance

Executive Chairman of Shanghai Chest Pain Center Alliance  …

多年来从事心血管疾病的临床和科研工作，能熟练进行冠心病导管介入治疗、房颤冷冻消融术、左心耳封堵术、心脏生理性永久起搏器安装术、先天性心脏病介入治疗🚣🏽、动脉粥样硬化性外周血管病介入治疗、激光销蚀术🤛🏽、冠状动脉内膜旋磨术等多种介入治疗技术👩🏿‍🔧。擅长经桡动脉径路整体治疗冠心病😦，致力于急性心肌梗死救治三十余年🧲。多次被邀请港澳台及国内顶尖会议担任手术演示嘉宾。近年来，我中心急性心肌梗死抢救上海位列前二。十院胸痛中心已成为中国胸痛中心示范基地，并为中国胸痛中心区域再认证中心(全国仅两家)。率先国内开展左心耳封堵术治疗房颤👱🏽🦹🏼‍♀️，房颤消融+左心耳封堵的“一站式手术”位列亚太前列🥺。中心已成为中国首批房颤中心，并被认定为“中国房颤中心示范基地”。担任中国心脏康复中心工作委员会执行主任，积极推进心脏康复中心建设，建立“葛均波现代心脏康复中心”。 D-SPECT（十院单中心样本量全球最大）精准评估下🫄🏼🕵️，首创“体外震波+体外反搏+干细胞”序贯治疗缺血性心肌病，开启精准康复治疗新时代。中心已成为中国首批心衰建设单位↖️。

作为PI主持VIS PMS、TOTAL☎、VIVE等数项大型国际、国内多中心临床试验。作为亚太地区唯一PI共同主持全球大型多中心临床的TOTAL研究，研究结果作为共同作者发表于《New England Journal of Medicine》（IF= 55.4）。单中心急性心梗院内死亡率仅1.32%，达到国际一流水平。

建立“院前院内”急性心肌梗死信息化急救平台♦️，全球首创“移动PACS”和“D2D”系统🐹🥒，获“科技部国家重点研发项目（4124万元）”、上海市“第四轮（4155万元）三年行动计划”资助。并已辐射包括西藏🤴、云南等全国28家医院💪🏿。形成急性心肌梗死信息化救治网络，切实改善我国急性心梗救治区域不平衡问题。

作为负责人先后承担科技部国家重点研发项目1项、国家自然科学基金面上项目3项📳、上海市公共卫生体系建设三年行动计划第三、第四轮各1项😷、上海市重要疾病联合攻关重大项目1项、上海市第四轮公共卫生三年行动计划重点学科建设计划1项、科技部十二五支撑计划1项、863项目子课题1项等，科研经费总计逾亿元。近五年发表各类文章351篇 ,包括《JAMA》🤾🏻‍♀️🏌️‍♂️、《JACC》等SCI文章82篇😄，累计影响因子近300分🧑🏼‍🚀。作为第一完成人荣获2017"中华医学科技奖"二等奖1项，多次获得上海市科技进步奖👎🏻、上海医学科技奖等。

Dr Yawei Xu has been engaged in clinical and scientific research of cardiovascular disease for more than 30 years, and is proficient in catheter interventional therapy for coronary heart disease, cryoablation of atrial fibrillation, left atrial appendage closure, cardiac physiologic permanent pacemaker implantation, interventional therapy for congenital heart disease, interventional therapy for peripheral artery disease, laser ablation, and rotational atherectomy. He is especially good at the overall treatment of coronary heart disease through the radial artery approach, and has been endeavored to the treatment of acute myocardial infarction for many years.

He is also the chairman or vice chairman of many national medical alliances, which includes Chinese Medical Association Internal Medicine Branch, the Cardiovascular Medicine Branch of the Shanghai Medical Association, Chinese Cardiovascular Physicians in the World Executive Vice President and Secretary General of the Association (WACC), China Chest Pain Center Alliance, China Atrial Fibrillation Center Alliance, etc..

As a PI, Dr Xu presided over several large-scale international and domestic multi-center clinical trials such as VIS PMS, TOTAL, and VIVE. He also co-hosted a global large-scale multi-center clinical TOTAL study as the only PI in Asia-Pacific region, and the results were published as a co-author in the New England Journal of Medicine (IF= 55.4). In the past five years, he has published 351 articles, including 82 SCI articles such as JAMA and JACC, with a cumulative impact factor of nearly 300 points. As the first completer, he won the second prize of 2017" China Medical Science and Technology Award", and won the Shanghai Science and Technology Progress Award, and Shanghai Medical Science and Technology Award for many times. He has served as an evaluation expert in the China Medical Science and Technology Award, and the Shanghai Science and Technology Award for several times. He has also been invited to Hong Kong, Macao, Taiwan, and domestic top conferences for many times as a interventional demonstration guest.